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Abstract
Context
There are growing concerns about effect size inflation and replication validity of association
studies, but few observational investigations have explored the extent of these problems.
Objective
Using meta-analyses to measure the reliability of initial studies and explore whether this var-
ies across biomedical domains and study types (cognitive/behavioral, brain imaging,
genetic and “others”).
Methods
We analyzed 663 meta-analyses describing associations between markers or risk factors
and 12 pathologies within three biomedical domains (psychiatry, neurology and four
somatic diseases). We collected the effect size, sample size, publication year and Impact
Factor of initial studies, largest studies (i.e., with the largest sample size) and the corre-
sponding meta-analyses. Initial studies were considered as replicated if they were in nomi-
nal agreement with meta-analyses and if their effect size inflation was below 100%.
Results
Nominal agreement between initial studies and meta-analyses regarding the presence of a
significant effect was not better than chance in psychiatry, whereas it was somewhat better
in neurology and somatic diseases. Whereas effect sizes reported by largest studies and
meta-analyses were similar, most of those reported by initial studies were inflated. Among
the 256 initial studies reporting a significant effect (p<0.05) and paired with significant meta-
analyses, 97 effect sizes were inflated by more than 100%. Nominal agreement and effect
size inflation varied with the biomedical domain and study type. Indeed, the replication rate
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of initial studies reporting a significant effect ranged from 6.3% for genetic studies in psychi-
atry to 86.4% for cognitive/behavioral studies. Comparison between eight subgroups shows
that replication rate decreases with sample size and “true” effect size. We observed no evi-
dence of association between replication rate and publication year or Impact Factor.
Conclusion
The differences in reliability between biological psychiatry, neurology and somatic diseases
suggest that there is room for improvement, at least in some subdomains.
Introduction
Many opinion and review articles have lamented the poor reproducibility of biomedical studies
(e.g., [1–4]). However, relatively few empirical studies have quantitatively explored this issue
across preclinical, clinical and association studies. The reproducibility of preclinical studies has
been recently reviewed [5]; five studies estimated the prevalence of irreproducible results in
preclinical studies to be between 51 and 89%. Regarding clinical trials of new treatments, two
lines of evidence point to the low replication validity of initial studies. First, only 40% of phase
II trials claiming a significant benefit of new drugs are confirmed when those drugs are subse-
quently tested in phase III trials [6, 7]. Second, most initial studies of a new treatment report a
larger effect than subsequent studies or meta-analyses on the same topic [8–10, 11, 12]. Simi-
larly, initial studies reporting a significant genetic association with various pathologies are
often shown to report inflated effects when compared to the results of subsequent studies [13–
15]. When the effect sizes associated with biomarkers reported in 35 highly cited studies were
compared to those reported in the corresponding meta-analyses [16], 14 were initial studies
reporting a significant association, of which one was disconfirmed by the corresponding meta-
analysis and seven reported an effect size at least twice as large as that the one indicated in the
corresponding meta-analysis.
The methods used in the four studies listed above were different. Two selected initial studies,
and then searched for subsequent studies on the same topic [14, 16]. The other two exploited a
database of 36 meta-analyses [13] that was extended to 55 meta-analyses [15]. Meta-analyses
provide a unique way to compare initial findings with subsequent studies, and this approach
has been used by Ioannidis and colleagues to estimate the replication validity of clinical trials
[8–11]. Unfortunately, this approach cannot yet be widely used for preclinical studies because
only a few meta-analyses exist in this area. In contrast, numerous recent meta-analyses have
tested the association between markers or risk factors and various diseases. Because this type of
biomedical research is crucial for improving the understanding and diagnosis of diseases, an
estimate of the replication validity of these studies is timely. Since the four previously published
estimates [13–16] mainly focused on genetic associations and were based on a relatively small
number of meta-analyses, we decided to investigate this question on a larger scale.
According to Button and colleagues [17], “the average statistical power of neuroscience
studies is very low. The consequences of this include overestimates of effect size and low repro-
ducibility of the results.” Their analysis used a database of 49 meta-analyses published in 2011
in the field of neuroscience, most pertaining to psychiatric disorders or neurological diseases.
This raises two questions. First, is the replication rate of initial studies in psychiatry similar to
neurology? Second, how do these compare to a sample of somatic diseases? The present study
was designed to address both questions. To assess the credibility of studies investigating the
association of markers or risk factors with diseases, we collected all meta-analyses published
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during a five year period related to four psychiatric disorders (attention deficit hyperactivity
disorder (ADHD), autism, unipolar depression, schizophrenia), four neurological diseases
(Alzheimer and Parkinson diseases, epilepsy and multiple sclerosis) and four somatic diseases
(breast cancer, glaucoma, psoriasis and rheumatoid arthritis). We aimed to test whether initial
studies were in agreement with the corresponding meta-analyses and to calculate their effect
size inflation. We then explored several factors that might influence discrepancies between ini-
tial studies and meta-analyses: the level of statistical significance of the corresponding meta-
analyses and of the initial studies, the biomedical domain, the study type (e.g., genetic), the
sample size, the journal Impact Factor and the publication year.
Methods
Selection of meta-analyses for Inclusion
We searched PubMed for relevant articles, with the search limited to articles referenced as
"meta-analysis" and published in English between January 1st 2008 and December 31st 2012.
Studies published online in 2012 but printed in 2013 or 2014 were also considered. We used
the following key words for each disease: “attention deficit hyperactivity disorder”, “autism”,
“major depressive disorder”, “epilepsy”, “Alzheimer disease”, “Parkinson disease”, “multiple
sclerosis”, “breast cancer”, “glaucoma”, “psoriasis” and “rheumatoid arthritis”.
Meta-analyses captured by this search strategy were screened by two authors (EDM and
FG) for eligibility. First, the title and the abstract were considered. Second, full texts were
obtained for the remaining studies and screened by two authors (EDM or FG). Articles were
excluded if: 1) they were related to the treatment, screening or diagnosis of the disease, 2) if
they reported on voxel-based brain imaging studies, 3) the disease itself was the risk factor for
another outcome, 4) no meta-analysis was conducted, or 5) the article was not related or rele-
vant to the disease. Meta-analyses were included if: 1) they compiled results from at least 7 dis-
tinct datasets reported in at least 4 independent publications, 2) the effect size was expressed as
mean difference, standardized mean difference (Cohen’s d), odds ratio (OR) or risk ratio (RR),
and 3) parameters were measured and/or validated by professionals (i.e., psychological traits
that were only self-assessed by subjects were not considered).
A number of articles reported several meta-analyses. We included all of them providing that
they were dealing with distinct parameters or risk factors. If an article reported several meta-
analyses on the same parameter and the same outcome, we selected the most comprehensive
one (i.e., the one containing the most datasets) and the one reporting the fixed effects rather
than the random effects model. When two or more articles dealt with the same parameter and
the same outcome, the most recent one was used. For genetic association studies, we used the
meta-analysis results for the allelic model when the data were available. However, when the
corresponding initial study put forward another model we selected this one.
Selection of initial studies and largest studies
From each meta-analysis we identified the initial study and we collected its full text article. We
checked them to assert that no study on the same topic was previously published. We thus
identified 110 initial studies that were not listed in the corresponding meta-analyses. These
omissions were mainly due to two reasons. First, a meta-analysis article of 36 associations
between brain imaging observations and schizophrenia explicitly mentioned that data pub-
lished before 1998 were not taken into account. Therefore, we looked for the “true” initial
studies. Second, initial studies were often replicated by the same group using an extended pop-
ulation and the second publication often included the initial data. Therefore, the corresponding
meta-analyses did not include the initial study. Nevertheless, we used here the data of the
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“true” initial studies. From each meta-analysis we also identified the largest study as the one
that included the largest number of patients.
Data extraction
Data were extracted independently by two authors (EDM and FG), and discrepancies resolved
by mutual consent. A third author (KB) conducted a further 10% data check, which resulted in
a small number of errors being detected and corrected. The following data were extracted from
initial, largest and meta-analysis articles: year of publication, first author, 2012 Impact Factor
of the journal that published it, nominal statistical significance (based on p<0.05), effect size,
its p-value for datasets reporting a significant effect or its confidence interval for non-signifi-
cant ones, number of patients and of healthy controls. Moreover, regarding meta-analyses we
also extracted the number of included datasets.
If the effect size was reported as a mean difference, it was converted to Cohen’s d using the
software OpenMetaAnalyst [18]. Meta-analyses and their corresponding initial and largest
studies were excluded if data were incomplete or if the reporting was unclear. In order to com-
pare the effect sizes across all meta-analyses and diseases, effect sizes were natural logarithm
transformed. The effect sizes expressed as Cohen’s d were converted to ln(OR) using the for-
mula ln(OR) = d × π/
p
3. For each disease, we calculated the average effect size of the initial
and largest studies as well as of the meta-analyses and the median of the number of patients.
These raw data are given in Supporting Information (S1 File).
Sensitivity and specificity analysis
In order to describe the nominal agreement between each initial study and its corresponding
meta-analysis we used, as previous authors have done [15], two concepts borrowed from bio-
medical diagnostic testing: sensitivity and specificity. In the context of our study, sensitivity
expresses the conditional probability that an initial study predicts a significant effect when a
significant effect is actually confirmed by the corresponding meta-analysis. Specificity
expresses the probability that an initial study reporting a non-significant effect corresponds to
a meta-analysis supporting the same view.
This agreement was coded according to four possibilities: 1) initial study and meta-analysis
both report a significant effect at p<0.05, 2) initial study and meta-analysis both report a non-sig-
nificant effect, 3) the initial study reports a significant effect whereas its associated meta-analysis do
not (false positive), and 4) the initial study reports a non-significant effect whereas the associated
meta-analysis reports a significant one (false negative). In addition we observed that six initial stud-
ies reporting a significant effect corresponded to meta-analyses reporting a significant effect in the
opposite direction. These six initial studies were coded as case 3 (false positive). The sensitivity and
specificity were calculated using the Clinical Calculator 1 (vassarstats.net). Their confidence inter-
vals at 95% were given by this online calculator according to Newcombe [19].
Defining a small effect
We used our dataset of meta-analyses reporting a significant association to define a small effect
in each of our four association types: cognitive/behavioral, brain imaging, genetic and other.
For each category we sorted in quintiles the significant effect sizes. The largest effect size of the
lowest quintile was defined as the maximal value of a small effect. All effects sizes of the 65 sig-
nificant cognitive/behavioral studies were expressed as standardized mean difference and a
small effect was estimated to be d 0.51. All but two effect sizes of the 69 significant brain
imaging studies were expressed as standardized mean difference. The two others were
expressed as odds ratio and were converted to standardized mean difference. This gave a small
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effect as d 0.29. All 136 significant genetic associations were expressed as odds ratio and a
small effect was defined as OR 1.11. Finally, the 146 significant “other” studies were first
devised into two categories: 60 were expressed as standardized mean difference and 96 as odds
ratios. Regarding the former, a small effect was d 0.30 and the latter was OR 1.20.
Statistical analyses
Effect sizes of initial or largest studies were compared to those of the corresponding meta-anal-
yses using Wilcoxon’s test for paired observations, as others have done with similar data [20,
21]. Other comparisons were tested using the χ2 test. The relationship between effect size infla-
tion and Impact factor was analyzed using linear regression and also Spearman’s rank correla-
tion. These statistical analyses were done using SigmaPlot software.
Results
Characteristics of included studies
We included 663 meta-analyses reporting an association between a marker or a risk factor and a
disease outcome in one of the three domains of interest (psychiatry, neurology and somatic dis-
eases). Among these, 66 meta-analyses were related to cognitive test or behavioral observation
and 97 to brain imaging studies. All but two meta-analyses were in the domain of psychiatry (see
Table 1). Genetic studies were widely represented in all three domains (Table 1). Finally, associa-
tions classified as “other” corresponded to a wide variety of studies (e.g., epidemiology, blood
tests, physical characteristics). Table 1 summarizes the number of articles selected at each step of
the process, and the number of meta-analyses included for each pathology. The selection of stud-
ies is also shown in flow diagrams (see supporting information S1 Fig).
Do initial studies agree with subsequent meta-analyses?
As previous authors have done [15], we calculated the sensitivity and specificity of initial stud-
ies to predict the presence or absence of an association indicated by the corresponding meta-
analysis (defined as statistically significant at p<0.05). The sensitivity of initial studies ranged
from 0.58 to 0.64 and was very similar across the three biomedical domains (Table 2). In con-
trast, the specificity ranged from 0.47 to 0.70 (Table 2) and there was some evidence that this
was lower for initial studies in psychiatry when compared to neurology (χ2 test: p = 0.0055)
and somatic diseases (p = 0.059). We used a ROC diagram to plot the sensitivity as a function
of (1-specificity). This indicated that the agreement between initial studies and corresponding
meta-analyses may not be better than chance in psychiatry whereas it was somewhat better in
neurology and somatic diseases (Fig 1).
Previous studies have shown that meta-analyses reporting a significant effect at p<0.05 are
sometimes disconfirmed by subsequent meta-analyses whereas those reporting stronger statis-
tical evidence (p<0.005) were rarely disconfirmed [20, 22]. This higher level of statistical strin-
gency may increase the credibility of scientific research [23]. Furthermore, a meta-analysis
reporting a non-significant effect only means that its confidence interval contains the null
value, but does not prove the absence of an association. However, the confidence interval can
be used to reject an effect larger than a predefined threshold [24]. If the 95% confidence inter-
val excludes anything other than a small effect, the study under consideration is able to reject a
larger effect. However, there is no general rule that defines what is a small effect–it depends on
the type of association [22]. Here we used our database of 425 significant associations reported
by meta-analyses to define a small effect in each of our four association types: cognitive/behav-
ioral, brain imaging, genetic and other (see Methods).
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We therefore conducted a sensitivity analysis where we restricted our analysis to associations
investigated by stringent meta-analyses. We defined a meta-analysis as stringent either if it reported
an effect as significant at p<0.005 or, when non-significant, if its confidence interval excluded a
threshold effect, as determined relatively to typical effect sizes in that field. Using these criteria we
categorized 385 meta-analyses as stringent, of which 326 reported a significant effect (Table 2).
When initial studies were compared to these corresponding stringent meta-analyses, sensitivity and
specificity remained similar to those observed when all 663 associations were considered (Table 2).
Again, the ROC diagram shows that the agreement between initial studies in psychiatry and their
corresponding stringent meta-analyses might not be better than chance (Fig 1).
Do initial studies report inflated effect sizes?
Even if initial studies and corresponding meta-analyses both report a significant effect, initial
studies might be misleading by reporting an inflated estimate of the effect size. Among the 256
Table 1. Number of studies identified in three research domains.
Psychiatric disorders Neurological diseases Somatic diseases
ADHD ASD MDD SCZ AD Epi MS PD BC Glau Pso RA
PubMed
search
118 71 553 454 197 147 137 139 811 75 81 285
Examined
full texts
43 36 114 198 117 29 44 74 345 19 22 82
Included
articles
20 13 28 59 35 12 18 20 89 9 8 22
Included
meta-
analyses
40 24 53 203 50 15 37 57 114 21 15 34
Cognitive/
behavioral
14 0 9 43 1 0 0 1 0 0 0 0
Brain
imaging
2 10 19 64 1 1 0 0 0 0 0 0
Genetic
studies
12 4 8 56 33 3 17 30 61 17 12 31
Other
studies
12 10 17 40 15 11 20 26 53 4 3 3
ADHD: attention deﬁcit hyperactivity disorder. ASD: autism spectrum disorder. MDD: major depressive disorder. SCZ: schizophrenia. AD: Alzheimer
disease. Epi: epilepsy. MS: multiple sclerosis. PD: Parkinson disease. BC: breast cancer. Glau: glaucoma. Pso: psoriasis. RA: rheumatoid arthritis.
doi:10.1371/journal.pone.0158064.t001
Table 2. Diagnostic performance of initial studies against the statistical significance of the correspondingmeta-analyses.
PSY NEURO SOMA
All meta-analyses 320 159 184
signiﬁcant meta-analyses 221 (69.1%) 100 (62.9%) 104 (56.5%)
sensitivity 0.612 (0.544 0.676) 0.636 (0.533 0.729) 0.584 (0.482 0.680)
speciﬁcity 0.475 (0.376 0.577) 0.700 (0.566 0.808) 0.614 (0.501 0.717)
Stringent meta-analyses 205 85 95
signiﬁcant meta-analyses 178 (86.8%) 77 (90.6%) 71 (74.7%)
sensitivity 0.625 (0.549 0.696) 0.649 (0.531 0.752) 0.718 (0.597 0.816)
speciﬁcity 0.533 (0.346 0.712) 0.875 (0.477 0.993) 0.625 (0.408 0.804)
PSY: psychiatric disorders; NEURO: neurological diseases; SOMA: somatic diseases.
Conﬁdence intervals at 95% are given in parentheses.
doi:10.1371/journal.pone.0158064.t002
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initial studies reporting a significant effect and paired with a meta-analysis reporting a signifi-
cant effect in the same direction, 150 initial studies (59%) reported an effect size inflated by more
than 50%, of which 97 were inflated by more than 100%.When we analyzed the 12 pathologies
under consideration separately, the average effect size reported by initial studies was always larger
than that reported by subsequent meta-analyses (Fig 2A). In contrast the effect size reported by
the corresponding largest studies were much more consistent with the meta-analyses (Fig 2B and
2D). Indeed, for all pathologies, the effect size distribution differed between those reported by
initial studies and those reported by meta-analyses (Wilcoxon’s test for paired observations).
There was clear statistical evidence for most of these differences (p<0.002) except for autism
(p = 0.025), epilepsy (p = 0.02) and psoriasis (p = 0.009). A similar pattern was observed when
considering only initial studies reporting a significant effect (Fig 2C).
Are initial studies consistent with subsequent meta-analyses?
To summarize the consistency between initial studies and corresponding meta-analyses we
classified as replicated: i) initial studies reporting a non-significant effect and corresponding to
non-significant meta-analyses, and ii) initial studies reporting a significant effect and corre-
sponding to significant meta-analyses providing that the inflation of the effect size did not
exceed a certain percentage threshold. We tested two inflation thresholds: 100% and 50%
(Table 3). Regardless of the threshold, initial studies dealing with psychiatric disorders were
less often in agreement with the corresponding meta-analyses than those dealing with neuro-
logical diseases (Table 3). However, there was no evidence that replication rates differed
between psychiatric disorders and somatic diseases (Table 3). We also analyzed initial studies
reporting a significant effect only and we did not observe any evidence of a difference between
the three biomedical domains (Table 3).
Fig 1. ROC diagram expressing the sensitivity and specificity of initial studies in agreeing with
correspondingmeta-analyses regarding the presence or absence of a nominally significant effect. For
the three biomedical domains the diagram either considered all 663 pairs of initial studies and meta-analyses
(circles) or only the 385 initial studies paired with stringent meta-analyses (triangles). Error bars represent the
confidence intervals at 95%. The dashed diagonal line corresponds to no discrimination above chance. The
fact that errors bars related to psychiatry cross this line suggests that the agreement between initial studies
and corresponding meta-analyses might not be better than chance. PSY: psychiatry; NEURO: neurology;
SOMA: somatic diseases.
doi:10.1371/journal.pone.0158064.g001
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Fig 2. Comparison between effect sizes reported by initial or largest studies and their corresponding
meta-analyses. All effect sizes were expressed as LnOR (standardized mean differences were converted to
LnOR as described in the Methods). (A) and (C) Mean of the effect sizes reported by initial studies for each
pathology. (B) and (D) Mean of the effect sizes reported by largest studies for each pathology. (A) and (B) All
663 trios were considered. (C) and (D) Only the 359 initial studies reporting a significant effect and their
corresponding largest studies. The dashed lines correspond to equality between the effect sizes of the initial
studies or of the largest studies and the effect sizes reported by the meta-analyses. PSY: psychiatry;
NEURO: neurology; SOMA: somatic diseases.
doi:10.1371/journal.pone.0158064.g002
Replication Validity of Initial Association Studies
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Table 3. Number of initial studies consistent with correspondingmeta-analyses.
number of studies comparisons
PSY NEURO SOMA PSY / PSY / NEURO /
# % # % # % NEURO SOMA SOMA
All initial
studies
320 159 184
initial
consistent
(inﬂation
100%)
131 40.9 85 53.5 84 45.7 p = 0.0094 p = 0.30 p = 0.15
initial
consistent
(inﬂation
50%)
101 31.6 71 44.7 75 40.8 p = 0.0049 p = 0.037 p = 0.47
Only initial
reported as
signiﬁcant
number of
studies
187 81 91
initial
consistent
(inﬂation
100%)
83 44.4 43 53.1 33 36.3 p = 0.19 p = 0.20 p = 0.27
Only highly
signiﬁcant
initial
number of
studies with
p < 0.005
94 44 48
initial
consistent
(inﬂation
100%)
42 44.7 23 52.3 23 47.9 p = 0.41 p = 0.71 p = 0.68
Without
cognitive/
behavioral
254 157 184
initial
consistent
(inﬂation
100%)
90 35.4 84 53.5 84 45.7 p = 0.0003 p = 0.031 p = 0.15
initial
consistent
(inﬂation
50%)
70 27.6 71 45.2 75 40.8 p = 0.0003 p = 0.0039 p = 0.41
Only initial
reported as
signiﬁcant
number of
studies
142 79 91
initial
consistent
(inﬂation
100%)
45 31.7 42 53.2 33 36.3 p = 0.0019 p = 0.47 p = 0.028
PSY: psychiatric disorders; NEURO: neurological diseases; SOMA: somatic diseases.
doi:10.1371/journal.pone.0158064.t003
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When considering only initial studies paired with 385 stringent meta-analyses, these results
did not change substantially (Table 4). However, when considering only initial studies report-
ing a significant effect, the percentage of initial studies in agreement with corresponding strin-
gent meta-analyses was larger than those observed when considering all 663 pairs (see Table 4
vs Table 3). This is due to the fact that the percentage of meta-analyses reporting a non-signifi-
cant effect was much smaller when we only considered stringent meta-analyses (Table 2).
Therefore, the number of significant initial studies associated with non-significant stringent
meta-analyses was reduced.
Are highly significant initial studies more reliable?
We applied our criteria of a stringent study to initial studies by removing those reporting a sig-
nificant effect with a p-value>0.005 and those that did not exclude a small effect on the basis
of their confidence interval. On this basis only five of the 304 initial studies reporting a non-sig-
nificant effect were able to exclude a small effect and only one was consistent with the corre-
sponding meta-analysis. Of the 359 initial studies reporting a significant effect, only 186
reported a p-value<0.005. We compared their replication rate to that of all initial studies
reporting a significant effect (Table 3). We observed no difference. Therefore, initial studies
reporting a highly significant effect (p<0.005) are no more reliable than those reporting a p-
value between 0.05 and 0.005.
Does replication rate of initial studies differ by study type?
We tested whether the agreement of initial studies with their corresponding meta-analyses
depends on the biomedical domain and on the type of study. In order to do so, we defined a
replication rate as the percentage of initial studies that were in nominal agreement with meta-
analyses and whose effect size inflation was100%. In this subgroup analysis, we did not take
into account four associations with neurological diseases (two brain imaging and two cogni-
tive/behavioral studies) due to the small number of studies. We thus considered eight homoge-
nous subgroups. Associations with psychiatric disorders were sorted into four subgroups:
Table 4. Number of initial studies consistent with corresponding stringent meta-analyses.
number of studies comparisons
PSY NEURO SOMA PSY /
NEURO
PSY / SOMA NEURO /
SOMA# % # % # %
All initial
studies
205 85 95
initial
consistent
(inﬂation
100%)
93 45.4 44 51.8 47 49.5 p = 0.32 p = 0.51 p = 0.76
Only initial
reported as
signiﬁcant
number of
studies
124 51 60
initial
consistent
(inﬂation
100%)
77 62.1 37 72.5 32 53.3 p = 0.19 p = 0.26 p = 0.037
PSY: psychiatric disorders; NEURO: neurological diseases; SOMA: somatic diseases.
doi:10.1371/journal.pone.0158064.t004
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cognitive/behavioral, brain imaging, genetic and “other” studies. Associations with neurologi-
cal and somatic diseases were both sorted into two subgroups: genetic and “other” studies.
Table 5 gives the number and percentage of initial studies that were consistent with their corre-
sponding meta-analyses in each subgroup, whether considering all 659 meta-analyses or only
the 382 defined as stringent. Data restricted to initial studies reporting a significant effect are
given in Table 6.
Tables 5 and 6 show that the replication rate of initial studies differs considerably between
subgroups. Within psychiatry, initial studies of cognitive/behavioral associations exhibited the
highest replication rate, whereas those regarding genetic associations were the least replicated.
As all but two cognitive/behavioral meta-analyses were related to psychiatric disorders, we also
Table 5. Replication rate of initial studies in 8 subgroups.
All meta-analyses Stringent meta-analyses
# stud # consist % # stud # consist %
Psychiatry
Cognitive/
behavioral
66 41 62.1 65 41 63.1
Brain imaging 95 36 37.9 55 23 41.8
Genetic 80 26 32.5 26 7 26.9
“Other” studies 79 28 35.4 59 22 37.3
Neurology
Genetic 83 40 48.2 39 16 41.0
“Other”
associations
72 42 58.3 43 26 60.5
Somatic diseases
Genetic 121 60 49.6 57 32 56.1
“Other”
associations
63 24 38.1 39 16 41.0
Initial studies are consistent if inﬂated by 100% or less.
doi:10.1371/journal.pone.0158064.t005
Table 6. Replication rate of significant initial studies in 8 subgroups.
All meta-analyses Stringent meta-analyses
# stud # consist % # stud # consist %
Psychiatry
Cognitive/
behavioral
45 38 84.4 44 38 86.4
Brain imaging 50 21 42.0 28 18 64.3
Genetic 46 3 6.5 16 1 6.3
“Other” studies 46 21 45.7 36 20 55.6
Neurology
Genetic 37 14 37.8 19 11 57.9
“Other”
associations
41 27 65.9 29 24 82.8
Somatic diseases
Genetic 61 24 39.3 40 24 60.0
“Other”
associations
30 9 30.0 20 8 40.0
Initial studies are consistent if inﬂated by 100% or less.
doi:10.1371/journal.pone.0158064.t006
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compared the replication rate of initial studies in the three domains when restricting the analy-
sis to biomarkers and biological risk factors (Table 3). This analysis shows that initial studies in
biological psychiatry were less reliable than those of both other biomedical domains.
Does replication rate depend on sample size and “true” effect size?
In order to elucidate the factors contributing to the replication rate of initial studies, we built
three-dimensional graphs expressing for each subgroup how the replication rate was related to
the “true’ effect size (i.e., the effect size reported by stringent meta-analyses) and to sample size
(i.e., the number of patients in initial studies) (Fig 3). Whether considering all initial studies
Fig 3. Replication rate of initial studies depending on the “true” effect and on the sample size. The
replication rate was calculated for the eight subgroups as the percentage of initial studies that were consistent
with meta-analyses and whose effect size inflation was100% (raw data are given in Tables 5 and 6). The
average of the “true” effect size was the mean of the summary effect size reported by each stringent meta-
analysis for each subgroup. The sample size corresponded to the median of the number of patients of all
initial studies in each subgroup and was represented as the area of the circles (same scale for (A) and (B)).
(A) All initial studies paired with stringent meta-analyses (n = 382). (B) Only initial studies reporting a
significant effect and paired with stringent meta-analyses (n = 232). BI: brain imaging studies; C/B: cognitive/
behavioral studies; PSY: psychiatric disorders; NEURO: neurological diseases; SOMA: somatic diseases.
doi:10.1371/journal.pone.0158064.g003
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(Fig 3A) or only those reporting a significant effect (Fig 3B), subgroups exhibiting the lowest
replication rates were associated with either a smaller “true” effect size or a lower sample size
or both.
Are largest studies more reliable?
We used the same procedures to evaluate the performance of largest studies against their
corresponding meta-analyses. With respect to the nominal agreement with corresponding meta-
analyses, the sensitivity of largest studies (Table 7) was similar to that of initial studies (Table 2),
but their specificity was better. This was true either when all 663 associations were considered or
when the analysis was restricted to stringent meta-analyses (Table 7). Moreover, there was no evi-
dence that the performance of the largest studies differed between the three domains (Table 7).
The replication rate of largest studies was much better than that of initial studies. It ranged
from 62.5% to 67.9% when all largest studies were considered, and from 70.6% to 80.4% when
only significant largest studies were taken into account. Again, we observed no significant dif-
ference between the three domains.
Are studies published in high Impact Factor journals more reliable?
In our sample of 663 associations, initial studies dealing with psychiatric disorders were pub-
lished in scientific journals exhibiting a higher Impact Factor than those dealing with neurolog-
ical diseases or with our set of somatic diseases (Impact Factor median: 7.7 versus 4.8 versus
5.6, respectively). However, there was no statistical evidence that the Impact Factor distribu-
tions differed between the three domains.
To test the association of Impact Factor and the replication rate of initial studies, we calcu-
lated an inflation index for every initial study defined as the ratio of its effect size divided by
the effect size reported by the corresponding meta-analysis [25]. We plotted this ratio against
the Impact Factor of the journal that published the initial study. Data were analyzed using lin-
ear regression. This analysis was performed separately for each three domains and for the eight
subgroups. No negative relationships where observed. We found no evidence of a positive rela-
tionship between inflation score and Impact Factor except in three subgroups: genetic studies
related to psychiatry (r2 = 0.06, p = 0.026, n = 80) and to neurology (r2 = 0.06, p = 0.025,
n = 83) as well as “other” studies related to somatic diseases (r2 = 0.11, p = 0.008, n = 63). Nev-
ertheless, the strength of association in each case was modest. We also tested whether the infla-
tion index was correlated with the Impact factor using Spearman’s rank correlation. None of
the eleven tested associations reached statistical significance at p<0.05.
Table 7. Diagnostic performance of largest studies against the statistical significance of the corre-
spondingmeta-analyses.
PSY NEURO SOMA
All meta-analyses 320 159 184
sensitivity 0.586 (0.518 0.652) 0.646 (0.543 0.738) 0.538 (0.438 0.636)
speciﬁcity 0.82 (0.728 0.887) 0.817 (0.691 0.901) 0.85 (0.749 0.917)
Stringent meta-
analyses
205 85 95
sensitivity 0.669 (0.594 0.736) 0.795 (0.686 0.875) 0.643 (0.519 0.751)
speciﬁcity 0.926 (0.742 0.987) 1 (0.598 1) 0.875 (0.665 0.967)
PSY: psychiatric disorders; NEURO: neurological diseases; SOMA: somatic diseases.
Conﬁdence intervals at 95% are given in parentheses.
doi:10.1371/journal.pone.0158064.t007
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Does publication year influence the reliability?
In our sample of 663 initial studies only 40 were published before 1980 and none in 2010 or
later. Therefore, in order to test a possible influence of the publication year we sorted our sam-
ple into four groups, those published before 1980 and those published during the last three
decades (1980s, 1990s and 2000s). There was no evidence that publication year was associated
with the replication rate of initial studies whether analyzing all associations together or consid-
ering each three domains separately.
However, among genetic studies, the publication year of initial studies reporting a significant
effect deserves to be examined in detail. Indeed, in our sample of initial studies, only 2/46 psychi-
atric studies were published between 2005 and 2009 whereas for neurological and somatic dis-
eases 17/37 and 22/61 studies were published during this five-year period, respectively. Because
for neurological and somatic subgroups the sample size increased more than six-fold during this
period, due to the growth in large collaborative studies, the replication rate of their initial studies
was three times larger than for those published before 2005. Thus, the fact that our sample of ini-
tial genetic studies related to psychiatry included only two studies published after 2004 partly
contributes to the overall impression that they were less often replicated (Table 6).
Are initial studies representative of later studies?
Fig 4 shows the relationship between the number of patients in initial studies and the average
number of patients in subsequent ones. This average number of patients was calculated by sub-
tracting the number of patients in initial studies from the total number of patients included in
each meta-analysis and by dividing it by the number of datasets minus one. For the eight sub-
groups, the sample size of initial studies was always smaller than for the averaged subsequent
Fig 4. Relationship between the number of patients in initial studies and the average number of
patients in subsequent studies. The average number of patients in subsequent studies was calculated by
subtracting the number of patients in initial studies from the total number of patients included in each meta-
analysis and by dividing it by the number of datasets minus one. The 659 averaged sample sizes of
subsequent studies were sorted in eight subgroups and we calculated the median for each subgroup. These
eight medians were plotted as a function of the medians of the number of patients in initial studies for each
subgroups. The dashed line corresponds to equality between both median types. BI: brain imaging studies;
C/B: cognitive/behavioral studies.
doi:10.1371/journal.pone.0158064.g004
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studies, but with noticeable differences (Fig 4). The average sample size of subsequent studies
was at least twice as large as for initial studies regarding three subgroups: somatic studies in
genetics as well as neurological and somatic studies of the “other” type (ratio: 2.4, 2.3 and 7.5,
respectively). Because in these three subgroups the subsequent studies included, on average,
many more patients, many are expected to be more reliable than initial studies. In contrast,
concerning the five other subgroups (i.e., the four subgroups related to psychiatry and the
genetic neurological studies), the number of patients in subsequent studies was, on average,
only 1.4 to 1.6 times larger than that of the corresponding initial studies. Therefore, the replica-
tion rate of these subsequent studies would be expected to be similar to that of the correspond-
ing initial studies. However, this warrants further research.
Comments
Our observations confirm that the replication validity of association studies is low. The agree-
ment between initial studies and their corresponding meta-analyses regarding the presence or
absence of a significant effect is not better or only poorly better than chance depending on the
biomedical domain. Moreover, 43% of initial significant studies paired with a significant meta-
analysis reported an effect size inflated by more than 100%. Our major finding is that lack of
replication validity and effect size inflation differ across biomedical domains and study types.
Among initial studies reporting a significant effect, the replication rate ranged from 6.3% for
genetic studies of psychiatric disorders to 86.4% for cognitive/behavioral studies of psychiatric
disorders. When comparing the three biomedical domains we observed no major differences,
but when this comparison was restricted to biomarkers and biological risk factors, initial stud-
ies related to biological psychiatry appeared less reliable than those of both other domains.
Button and colleagues suggested that small sample size undermines the reliability of many
neuroscience studies [17]. The present study reaches the same general conclusion and extends
it. First, in our samples, initial neurological studies are at least as reliable as those related to a
set of four somatic diseases. Second, cognitive/behavioral initial studies related to psychiatric
disorders appeared much more reliable than other psychiatric studies. Third, initial studies
related to biological psychiatry are less reliable than those related to neurological diseases.
Theoretical simulations show that small sample size undermines reproducibility and
increases effect size inflation [1, 17, 26]. Previous observational studies [9, 11, 27] as well as the
present study support this view. Moreover, the comparisons between eight subgroups illustrate
that the relationship between sample size and effect size inflation is relative. When the “true”
effect size is large, as in our sample of cognitive/behavioral studies, even initial studies with a
small sample size are replicated. In contrast, initial genetic studies related to psychiatry were
less often replicated than in neurology not because their sample size was smaller but because it
was too small to accurately deal with a much smaller “true” effect size. The fact that the replica-
tion rate of largest studies is much better than that of initial studies further supports the view
that inadequate sample size is a major cause of low replication validity.
Three previous studies have already highlighted that many brain imaging studies report
inflated effect sizes [28–30]. In particular, Ioannidis evaluated the 461 primary datasets
included in 41 meta-analyses on the associations between psychiatric disorders and brain vol-
ume abnormalities [28]. This demonstrated that the number of primary studies reporting a sig-
nificant effect was about twice as large as what could be expected from the “true” effects
reported by the meta-analyses. Our observations regarding the 95 brain imaging studies related
to psychiatric disorders are consistent with this previous study.
The effect size inflation and the poor replication validity of candidate gene studies of com-
plex diseases have been already described [13, 15, 31]. In particular Trikalinos and colleagues
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analyzed 55 meta-analyses and showed that initial studies poorly predicted the presence or
absence of a nominally significant effect reported by the corresponding meta-analysis [15].
More surprisingly, but in agreement with our own observations, they showed that this predic-
tive value was not improved when considering only initial studies reporting a highly significant
effect (p<0.005).
In our sample, 38 out of 45 initial studies reporting a significant association between cogni-
tive/behavioral observations and psychiatric disorders were in agreement with the correspond-
ing meta-analysis. This represents a much better performance than expected. Indeed,
collaborative attempts to replicate observations in cognitive psychology showed that only 21
out of 42 initial studies reporting a significant effect were replicated [21]. Moreover, psycholog-
ical science suffers from the same reporting biases as biomedical science [32].
We observed weak positive relationships between the inflation score of initial studies and
the Impact Factor of the journal that published them for three subgroups including genetic
studies in psychiatry and neurology. No negative relationships where observed. Our observa-
tions are in agreement with the positive relationship previously reported regarding 81 primary
genetic studies related to psychiatry, although our relationships are clearly weaker [25]. Never-
theless, both studies at least suggest that the reliability of initial studies does not increase with
the journal Impact Factor and this conclusion has also been drawn about preclinical studies
[33].
Limitations
Our study is based on the view that the summary effect reported by a meta-analysis is a reliable
estimate of the “true” effect. For this reason we only considered meta-analyses dealing with at
least seven independent datasets published in at least 4 independent publications. Indeed, a
comparison between pairs of meta-analyses published at a five-years interval about the same
association showed that the change in summary effect size was inversely related to the number
of datasets [20]. Despite this selection criterion, it is likely that some meta-analyses of our sam-
ple still reported an inflated effect or even a false positive effect. Indeed, publication bias (i.e.,
the preferential publication of positive results) and the inclusion of primary studies with low
methodological quality are likely to inflate the effect size estimated by meta-analyses [34, 35].
However, without study pre-registration, these biases are difficult to detect. Several tests have
been proposed to identify publication bias in meta-analyses and to correct for it [34, 35, 36,
37], but these methods suffer from limitations and often require meticulous explicit modeling
of each potential source of bias [37, 38]. Ioannidis and colleagues propose two methods to
probe the robustness of meta-analyses that report a statistically significant effect at p<0.05 [20,
22, 39]. Both methods require no assumption about the sources of potential biases, but are not
easy to apply in the context of our large database. However, these studies inspired us to adopt a
simpler approach to identify, among nominally significant meta-analyses, those likely to retain
their statistical significance with the inclusion of further studies.
We hypothesized that meta-analyses reporting highly significant effects (p<0.005) are more
reliable than those reporting a p value between 0.05 and 0.005. This hypothesis is supported by
theoretical considerations and by observational studies. Indeed, this more stringent p-value
roughly corresponds to a Bayes factor of 50, which means than no more than one in 50 meta-
analyses would report a false positive effect [23]. Moreover, Pereira and colleagues (2011)
reported on 80 nominally significant (p<0.05) meta-analyses of clinical trials published in
2005 that were updated in 2010 with additional trials. Among them, four lost their statistical
significance in 2010 and all four had a p value between 0.005 and 0.05 in 2005. Likewise, using
a Bayesian approach, Ioannidis (2008) tested the effect of formal statistical significance on the
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credibility of 50 meta-analyses reporting a significant genetic association at p<0.05 [22].
Among them, 27 had a p value below 0.005 of which 26 were analyzed as providing at least a
strong support to the association. In contrast, none of the 23 genetic associations with a
reported p value between 0.5 and 0.005 provided a strong support.
Ioannidis listed small sample size and small “true” effect size as two major causes of replica-
tion failure [1]. However, he also highlighted other causes related to the methodological quality
of the studies and to the general characteristics of each research field (i.e., the number of associ-
ations tested, the influence of financial interests and the strength of the competition between
researchers) [1]. However, because these other causes of replication failure are difficult to iden-
tify and quantify, especially when considering a large database, they were not investigated in
the present study.
We collected and analyzed the data of 663 initial studies and their corresponding largest
studies and meta-analyses. We did not individually consider each of the 10,154 primary data-
sets included in these 663 meta-analyses. Therefore, while we provide direct data about the rep-
lication rate of initial and largest studies, we have only indirect and limited evidence regarding
that of other primary studies in each subgroup. Our emphasis on initial studies, and especially
on those reporting a significant effect, is justified by their influence on subsequent research
efforts [15], and by the fact that they are much more echoed by the media than subsequent
studies [40].
Our selection of 12 pathologies is partly arbitrary. Regarding neurological diseases we
excluded stroke because it is also a cardiovascular disease, traumatic brain injury because it is
accidental and autism, which is rather a psychiatric disorder. Thus, our selection of neurologi-
cal diseases includes all four severe diseases exhibiting the highest prevalence rate [41]. Our
selection of four psychiatric disorders is less systematic: it included two severe disorders
(autism and schizophrenia) and two less severe and more prevalent disorders (ADHD and uni-
polar depression). Finally, our selection of four somatic diseases is even more arbitrary. We
selected them because their biological causes and risk factors are still poorly elucidated and
because they cover a range of prevalence similar to that of both other domains.
Our sample of initial studies was extracted from meta-analyses built from at least seven pri-
mary datasets. We did not investigate initial studies not followed by meta-analyses or included
in less extensive meta-analyses. Therefore, our sample represents a tiny fraction of all studies
published during the last three decades about the association of a risk factor with one of our 12
pathologies. Indeed, among a random sample of 259 biomedical studies reporting observa-
tional data, only 6.2% were included in a systematic meta-analysis [42]. Whether our sample of
initial studies was representative regarding replication validity remains to be elucidated.
Conclusion
The poor replication validity of initial biomedical studies has been put forward to recommend
potential solutions that might improve it [4, 32, 43–45]. However, some of these recommenda-
tions might have unintended negative consequences [46]. Beside these recommendations, we
would like to emphasize the opinion voiced by the Open Science Collaboration [21]: “If initial
ideas were always correct, then there would hardly be a reason to conduct research in the first
place. A healthy discipline will have many false starts as it confronts the limits of the present
understanding”. Nevertheless, the differences between biological psychiatry, neurology and
somatic diseases suggest that there is room for improvement at least in some subdomains.
An unrecognized consequence of the low reliability of initial studies is not related to the sci-
entific process of uncertainty reduction per se, but to the media coverage of scientific findings.
We showed with the case of ADHD that newspapers preferentially echo initial findings and
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almost never inform the public when they are refuted or strongly attenuated although the
majority of them are [40]. Therefore, the present estimates of the replication rates of initial
studies in various domains and subdomains might be especially useful for journalists and for
scientists when they interact with journalists. Initial findings should always be described as ten-
tative, uncertain and requiring replication when reported in the scientific literature, the aca-
demic press releases and the media.
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